Is microneedling recommended for patients with rosacea, and what precautions should be taken if it is performed?

Microneedling for Rosacea

Microneedling, particularly fractional microneedling radiofrequency (FMRF), can be used as an effective adjunctive treatment for rosacea, especially for vascular features like persistent erythema, telangiectasia, and flushing that respond incompletely to standard pharmacologic therapy.

Current Standard Treatment Framework

The established treatment approach for rosacea follows a phenotype-based strategy rather than a rigid algorithm 1. Standard first-line pharmacologic options include topical metronidazole, azelaic acid, ivermectin, minocycline foam, encapsulated benzoyl peroxide, and oral doxycycline 40mg for inflammatory lesions 1. These FDA-approved therapies effectively reduce papulopustular lesions but often leave persistent vascular manifestations inadequately controlled 1.

Role of Microneedling in Rosacea Management

When to Consider Microneedling

Microneedling should be considered specifically for:

• Persistent facial erythema that remains after controlling inflammatory lesions
• Telangiectasia requiring physical intervention
• Flushing and burning sensations resistant to topical therapy
• "Difficult-to-treat" rosacea cases unresponsive to standard pharmacotherapy 2

Evidence for Efficacy

The most compelling recent evidence comes from a 2026 retrospective cohort study showing that combining microneedling with oral doxycycline 100mg achieved 57.5% treatment success for facial erythema versus only 25.0% with doxycycline alone (p<0.001) 3. This combination approach also demonstrated:

• Significantly greater improvement in flushing, capillary dilation, swelling, and burning sensations
• Markedly lower 6-month erythema relapse rate: 20.0% versus 68.4% with monotherapy 3
• No severe adverse events

Fractional microneedling radiofrequency specifically showed substantial benefits in a 2022 prospective study, with CEA score reduction from 2.65 to 1.56 and 44.12% success rate for centrofacial erythema 2. The treatment reduced hemoglobin content from 376.47 to 161.32, indicating decreased vascular prominence, without compromising skin barrier function 2.

Clinical Implementation Protocol

Treatment Regimen

Based on the strongest evidence:

• Three monthly microneedling sessions as the standard course 3
• For more severe cases: sessions every 2 weeks for the first 2 months, then monthly 4
• Combine with oral doxycycline 100mg daily for 12 weeks when treating both inflammatory and vascular features 3

Specific Technique Considerations

• Fractional microneedling radiofrequency (FMRF) demonstrates superior outcomes compared to standard microneedling alone 2, 5
• Non-insulated FMRF showed 91.67% IGA success and 58.82% flushing improvement in difficult-to-treat cases 2
• Can be combined with topical agents like tranexamic acid 10% for enhanced delivery and outcomes 6

Critical Precautions and Contraindications

Absolute Contraindications

• Active inflammatory flare with numerous papules/pustules - control inflammation first with pharmacotherapy
• Active infection or open wounds
• Patients on anticoagulation (relative contraindication requiring assessment)

Essential Precautions

1. Stabilize inflammatory disease first: Achieve control of papulopustular lesions with topical or oral therapy before initiating microneedling 7
2. Avoid during acute flares: Microneedling during active inflammation may worsen symptoms
3. Sun protection is mandatory: SPF 30+ must be used consistently 1
4. Gentle skincare only: Avoid irritating products that could trigger flares 1

Expected Adverse Effects

• Transient erythema and mild swelling (expected and self-limited)
• No serious adverse events reported in clinical trials 3, 2, 4
• Relapse rate at 6 months: 20% with combination therapy versus 68.4% with pharmacotherapy alone 3

Integration with Standard Therapy

The optimal approach combines microneedling with appropriate pharmacologic management rather than using it as monotherapy. The 2017 ROSCO panel guidelines emphasize that moderate-to-severe presentations require combination treatments 7. While these guidelines predate the microneedling evidence, the principle applies:

• For inflammatory papules/pustules: Start with topical azelaic acid, ivermectin, or oral doxycycline 40mg 1, 7
• For persistent erythema after inflammatory control: Add microneedling sessions 3
• For telangiectasia: Consider FMRF as alternative to or in combination with IPL/laser 7, 8

Maintenance Strategy

After completing the initial 3-session course:

• Monitor for relapse at 6 months (occurs in 20% of combination therapy patients) 3
• Consider maintenance sessions every 3-4 months if relapse occurs
• Continue gentle skincare and trigger avoidance indefinitely 1
• Minimum treatment necessary to maintain control should be used 7

Comparative Effectiveness

A 2026 network meta-analysis found that radiofrequency microneedling was more effective than pulsed dye laser for both patient satisfaction (MD -1.32) and erythema reduction (MD -1.44) 8. This positions FMRF as a preferred energy-based device option when physical modalities are indicated.

The combination of microneedling with systemic isotretinoin (10mg daily) showed similar efficacy to microneedling alone but with lower relapse rates (16% versus 32%) and higher patient satisfaction (72% versus 32%) 4. However, isotretinoin carries significant contraindications and monitoring requirements that limit its use compared to doxycycline.

Common Pitfalls to Avoid

1. Performing microneedling during active inflammatory flares - this can exacerbate inflammation
2. Using microneedling as monotherapy for moderate-to-severe disease - always combine with appropriate pharmacotherapy
3. Inadequate sun protection post-procedure - increases risk of post-inflammatory erythema
4. Expecting immediate results - improvement typically becomes evident after 2-3 sessions
5. Failing to address trigger factors - microneedling treats manifestations but doesn't prevent flares from triggers